The Impact of Metformin on Hypothalamic–Pituitary–Thyroid Axis Activity and Thyroid Autoimmunity: A Protocol for Systematic Review
Pharmaceuticals · 06.11.2026 · 19 (11) · 1763
DOI: 10.3390/ph19111763 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Pharmaceuticals, online erschienen am 06.11.2026. Verfasst von Giovanni Cangelosi und 9 weiteren Autor:innen. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Metformin is one of the most frequently used insulin-sensitizing drugs. Type 2 diabetes (T2D) and other insulin-resistant states often coexist with thyroid pathology, and many patients with thyroid dysfunction and/or autoimmunity receive this agent. Despite theoretical premises, studies assessing the impact of metformin on thyroid-stimulating hormone (TSH), thyroid hormones, and thyroid antibody titers have provided inconsistent results.
Objective
This systematic review will identify, critically appraise, and synthesize the available evidence on the effects of metformin treatment on hypothalamic–pituitary–thyroid (HPT) axis activity and thyroid autoimmunity among adults receiving metformin for T2D or polycystic ovary syndrome.
Methods
Primary studies and grey literature examining the impact of metformin on HPT axis activity and thyroid autoimmunity will be included. Searches will be performed in MEDLINE via PubMed, Embase, Scopus, Web of Science and ClinicalTrials.gov registry, with no date or language restrictions. Google Scholar will be used exclusively during the preliminary search to identify relevant articles and inform search strategy development. After duplicate removal, two independent reviewers will conduct title and abstract screening in Rayyan, followed by full text assessment in JBI SUMARI according to the inclusion criteria. Disagreements will be resolved through preliminary discussion between the reviewers, and a third reviewer will be consulted for a final decision if necessary. Data extraction will be performed independently by two reviewers using a standardized extraction form. Where appropriate, random-effects meta-analysis will use mean differences or standardized mean differences for continuous outcomes, with Hartung–Knapp–Sidik–Jonkman confidence intervals. Heterogeneity will be assessed using I2 and τ2, alongside prediction intervals. Small-study effects will be assessed when at least 10 studies are available. Prespecified subgroup analyses will examine thyroid status, autoimmunity, diagnosis, treatment, and study design; sensitivity analyses will assess robustness. The review will be reported in accordance with the PRISMA 2020 statement. The certainty of the evidence will be assessed using the Grading of Recommendations, Assessment, Development and Evaluation approach. The protocol has been registered in the Open Science Framework.
Zitieren
APA
Cangelosi, G., Scerbo, F., Petrelli, F., Karuveettil, V., Kowalcze, K., Masini, A., Pantanetti, P., Caggianelli, G., Parozzi, M., & Krysiak, R. (2026). The Impact of Metformin on Hypothalamic–Pituitary–Thyroid Axis Activity and Thyroid Autoimmunity: A Protocol for Systematic Review. Pharmaceuticals, 19(11), 1763. https://doi.org/10.3390/ph19111763
Vancouver
Cangelosi G, Scerbo F, Petrelli F, Karuveettil V, Kowalcze K, Masini A, et al. The Impact of Metformin on Hypothalamic–Pituitary–Thyroid Axis Activity and Thyroid Autoimmunity: A Protocol for Systematic Review. Pharmaceuticals. 2026;19(11):1763. doi:10.3390/ph19111763
BibTeX
@article{Cangelosi2026,
author = {Cangelosi, Giovanni and Scerbo, Francesco and Petrelli, Fabio and Karuveettil, Vineetha and Kowalcze, Karolina and Masini, Alice and Pantanetti, Paola and Caggianelli, Gabriele and Parozzi, Mauro and Krysiak, Robert},
title = {The Impact of Metformin on Hypothalamic–Pituitary–Thyroid Axis Activity and Thyroid Autoimmunity: A Protocol for Systematic Review},
journal = {Pharmaceuticals},
year = {2026},
volume = {19},
number = {11},
pages = {1763},
doi = {10.3390/ph19111763}
}
EUVIMED